Skip to main content
M. Adel Aslani-Far

Adel Aslani-Far focuses his practice on cross-border and domestic public company mergers and acquisitions (including take-private transactions), corporate governance, and shareholder activism and takeover defense. He counsels large multinational corporations and other buyers and sellers on negotiated and hostile public M&A and going private transactions, as well as a broad range of private acquisitions and joint ventures around the world, in a broad range of industries including, among others, bio-pharmaceuticals, life sciences and medical devices; technology, media and telecommunications; energy and financial services. He also regularly counsels public company boards, board committees, and senior management on corporate governance and strategic planning, including shareholder activism and takeover defense preparedness and in defending against proxy contests and negotiating settlements with many of the most prominent activist funds. In addition, Mr. Aslani-Far has deep experience advising special committees of boards of directors in conflict of interest transactions.

In 2018, he was selected as a member of The Legal 500 US Hall of Fame for his M&A work, one of 14 M&A attorneys recognized for “constant praise by their clients for continued excellence.”

Concentrations

  • Cross-border and domestic public company M&A
  • Hostile acquisitions
  • Takeover defense
  • Shareholder activism defense
  • Private acquisitions
  • Joint ventures
  • Corporate governance and best practices for public company boards of directors

Capabilities

Experiencia

Mr. Aslani-Far's representative M&A transactions include advising:

Bio-Pharmaceuticals, Life Sciences and Medical Devices

  • Eli Lilly and Company in numerous transactions, including the:
    • $6.5 billion acquisition of ImClone Systems Inc.°
    • $2.1 billion acquisition of ICOS Corp.°
    • acquisition of Johnson & Johnson’s animal health business°
    • acquisition of Alnara Pharmaceuticals°
    • acquisition of a portfolio of animal health products from Pfizer and Wyeth°
    • acquisition of Monsanto Company’s animal health business°
    • equity investment in United Therapeutics Corp.°
    • acquisition of Hypnion, Inc.°
    • $400 million acquisition of Applied Molecular Evolution°
  • Novartis AG (Switzerland) in numerous transactions, including the:
    • $1.6 billion acquisition of worldwide rights to Famvir® from GlaxoSmithKline plc°
    • $862 million acquisition of 51% of Idenix Pharmaceuticals°
    • sale of the drug Brethine® to Neosan Pharmaceuticals and Aaipharma°
  • Zimmer Holdings in the $3.6 billion unsolicited cross-border acquisitions of Centerpulse AG and Incentive Capital AG, the first-ever hostile transaction in Switzerland°
  • Royal DSM N.V. (Netherlands) in numerous transactions, including:
    • the $2.6 billion joint venture with JLL Partners to form DPx Holdings B.V., a global leader in pharmaceutical contract development/manufacturing°
    • multiple equity investments in Amyris, Inc.°
  • Sorin S.p.A. (Italy) in its $3 billion cross-border merger-of-equals with Cyberonics Inc.°
  • Thoratec Corporation in the proposed sale of its International Technidyne subsidiary to Danaher Corporation°

Technology, Media & Telecommunications

  • The Walt Disney Company in numerous transactions including the:
    • up to $950 million acquisition of Maker Studios°
    • up to $763 million acquisition of Playdom Inc.°
    • $5.3 billion acquisition of Fox Family Worldwide Inc.°
    • $2.7 billion reverse Morris Trust tax-free divestiture of its ABC Radio business°
    • creation of, and ultimate exit from, the E! Channel Entertainment joint venture with Comcast Corporation°
  • Sony Corporation (Japan) in numerous transactions, including the:
    • $4.9 billion consortium take-private acquisition (with Providence Equity Partners, Texas Pacific Group and Comcast Corporation) of Metro-Goldwyn-Mayer.°
    • $453 million acquisition of InterTrust Technologies Corporation through a newly-formed joint venture with Royal Philips Electronics NV°
  • Siemens AG (Germany) in the $4.5 billion acquisition of Mentor Graphics Corp.°
  • Scripps Networks Interactive in the $2.4 billion acquisition of TVN SA (Poland) °
  • Rakuten Inc. (Japan) in numerous transactions, including the:
    • acquisition of Deep Forest Media°
    • acquisition of Viki Inc.°
    • equity investment in Daily Grommet°
  • Asian Food Channel (Singapore), a provider of food and lifestyle television programming, in its sale to Scripps Networks Interactive°
  • Ratos AB (Sweden) in the sale of two US operating subsidiaries to 3D Systems Corporation°

Energy

  • Siemens AG (Germany) in the $7.6 billion acquisition of Dresser-Rand Group°
  • Energy Capital Partners in its $16.6 billion consortium take-private acquisition of Calpine Corporation°
  • GSO Capital Partners in its acquisition of Energy Alloys LLC, a private company.°

Financial Services

  • Ares Capital in connection with its $3.4 billion acquisition of American Capital, a publicly traded private equity firm and asset manager with $20 billion of assets under management°
  • The Special Committee of the Board of Directors of Athene Holding Ltd. in connection with Athene’s reinsurance of $19 billion of fixed and fixed index annuities of Voya Financial°
  • Qatar Investment Authority (Qatar) in its strategic alliance with NYSE Euronext to create an integrated cash and derivatives exchange in Qatar°
  • Arrow Financial Services in its sale of a majority interest to Sallie Mae°

Other

  • Safeway Inc. in its $9.4 billion take-private acquisition by Cerberus Capital Management and Albertsons°
  • Booz Allen Hamilton in its $2.6 billion sale of a majority interest in its US Government Business to Carlyle Group°
  • Books-a-Million in its take-private transaction by the controlling Anderson family°
  • Body Central Corp. in its recapitalization°
  • GTCR in its $828 million take-private acquisition of Protection One, Inc.°
  • ACH Food Companies in its acquisition of Mazola® and related brands from Unilever plc°
  • The Talbots and AEON Inc. (Japan) in the $517 million acquisition of The J.Jill Group°
  • The Ackerley Group in its $800 million acquisition by Clear Channel Communications°
  • Major investment banking firms acting as financial advisors in numerous transactions, including:
    • Morgan Stanley and LionTree advising the Special Committee of Viacom in the $15.4 billion merger of CBS and Viacom°
    • Evercore advising Whole Foods in its activism defense against Jana Partners and its $13.4 billion acquisition by Amazon°

Mr. Aslani-Far counsels numerous public company clients on activism preparedness and responses to publicly disclosed and private campaigns by many of the most prominent activist funds, including Elliott Management, Engaged Capital, GAMCO Investors, Icahn Associates, JANA Partners, Raging Capital and Starboard Value, with deep experience defending against proxy contests and in negotiating settlements.°

°The above representations were handled by Mr. Aslani-Far prior to joining Greenberg Traurig, LLP.

Recognition & Leadership

  • The Legal 500 US
    • “Hall of Fame, United States M&A/Corporate and Commercial - M&A: Large Deals ($1bn+),” Member 2018 and 2020
    • M&A Mega-Deals (US$5 billion plus), M&A Large Deals (US$1 billion plus) and Shareholder Activism Defense, “Leading Lawyer” 2012-2019
  • Chambers Global, Corporate M&A (International & Cross-Border) USA, [Listed] 2020 
  • Chambers USA, New York Corporate/M&A, “Leading Lawyer” 2006-2020
  • Super Lawyers magazine, [Listed], 2008-2019
  • The National Law Journal, “Mergers & Acquisitions and Antitrust Trailblazers” 2015
  • Member, Association of the Bar of the City of New York, 2010-Present
    • Committee on Mergers, Acquisitions and Corporate Control Contests, 2010-Present
  • Member, American Bar Association

Credentials

Educación
  • J.D., Georgetown University, 1993
  • A.B., Columbia University, 1990
Con licencia para ejercer en
  • Nueva York